BioLineRx Ltd. (BLRX) stock
BLRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 20-F on Mar 23, 2026Score 3/30
$1.12−0.03 (-2.61%)
Close on Nov 17, 2026Market cap $4.87MP/E –Yield –
BioLineRx ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
For fiscal 2025 it was -$9.76M. The highest annual figure on record is -$9.76M in fiscal 2025.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$9.76M | – |
| FY2024 | Dec 31, 2024 | -$16.34M | – |
| FY2023 | Dec 31, 2023 | -$48.31M | – |
| FY2022 | Dec 31, 2022 | -$28.50M | – |
| FY2021 | Dec 31, 2021 | -$24.07M | – |
| FY2020 | Dec 31, 2020 | -$21.99M | – |
| FY2019 | Dec 31, 2019 | -$27.17M | – |
| FY2018 | Dec 31, 2018 | -$25.06M | – |
| FY2017 | Dec 31, 2017 | -$24.76M | – |
| FY2016 | Dec 31, 2016 | -$16.03M | – |
| FY2015 | Dec 31, 2015 | -$15.76M | – |
See a number that looks wrong?